Table 1. Characteristics of case patients with acute coronary syndrome and control patients derived from a nationwide cohort with schizophrenia (N = 31,177).
Characteristic, n (%) | Cases (n = 147) | Controls (n = 2940) | P-valuea |
---|---|---|---|
At first admission | Mean (SD) | Mean (SD) | |
Age, years | 45.7 (12.2) | 45.6 (12.0) | 0.131 |
n (%) | n (%) | ||
Men | 94 (64.0) | 1880 (64.0) | – |
Charlson comorbidity index | |||
1 | 102 (69.4) | 2457 (83.6) | Reference |
2 | 35 (23.8) | 400 (13.6) | <0.001 |
≥3 | 10 (6.8) | 83 (2.8) | 0.002 |
Within 180 days before the index date | |||
Physical illnesses | |||
Diabetes mellitus | 48 (32.7) | 276 (9.4) | <0.001 |
Cerebrovascular disease | 18 (12.2) | 51 (1.7) | <0.001 |
Chronic hepatic disease | 16 (10.9) | 155 (5.3) | 0.004 |
Hypertension | 57 (38.8) | 354 (12.0) | <0.001 |
Asthma | 10 (6.8) | 48 (1.6) | <0.001 |
Concomitant drugs | |||
Drugs used in diabetes | 48 (32.7) | 249 (8.5) | <0.001 |
Antihypertensives | 19 (12.9) | 69 (2.4) | <0.001 |
Agents acting on the renin-angiotensin system | 59 (40.1) | 185 (6.3) | <0.001 |
Lipid modifying agents | 36 (24.5) | 125 (4.3) | <0.001 |
Corticosteroids for systemic use | 39 (26.5) | 260 (8.8) | <0.001 |
Nasal preparations | 31 (21.1) | 449 (15.3) | 0.057 |
Drugs for obstructive airway diseases | 54 (36.7) | 460 (15.7) | <0.001 |
Cough and cold preparations | 83 (56.5) | 1099 (37.4) | <0.001 |
Antihistamines for systemic use | 71 (48.3) | 972 (33.1) | <0.001 |
Mood stabilizer | 26 (17.7) | 467 (15.9) | 0.560 |
Antidepressant | 37 (25.2) | 571 (19.4) | 0.088 |
aEstimated using univariate conditional logistic regression.